ProSign in / Sign upPrice source: Yahoo · live price · as of 23:00 · 289 trading days · fundamentals: yfinance
An algorithmic system based on technical data only — not investment advice. Trading is at your own risk.
Stock summary — overview
Free for allTechnically, IGC Pharma, Inc. is in a downtrend (below most moving averages), and momentum is weak. The weighted indicators point to “Strong Sell”. Analysts are pricing in avg target $4 (+1446%), strong buy. Institutional ownership is relatively low (23%). Market backdrop: Market leaning positive — S&P 500 below the 200-day SMA, 1-month return +nan%; VIX 16.9 (normal). Recent news sentiment: Mixed sentiment (4 positive / 3 negative). Bottom line: the balance of factors leans negative — caution, and consider reducing exposure.
Day
-0.29%
Week
-2.69%
Month
-2.52%
Year
-8.37%
IGC Pharma, New to The Street launch 12-part national media partnership
TipRanks · Mar 26, 2026
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
Zacks · Mar 19, 2026
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
Zacks · Mar 18, 2026
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Zacks · Mar 5, 2026
IGC Pharma expands Phase 2 CALMA trial with new clinical site
TipRanks · Feb 24, 2026
Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says
TipRanks · Dec 13, 2025
גילוי נאות וכתב ויתור: כל המידע, הציונים, האיתותים ותוכניות המסחר באתר מופקים על-ידי מערכת אלגוריתמית אוטומטית ומבוססים על נתונים טכניים וכמותיים בלבד. אין בהם משום ייעוץ השקעות, שיווק השקעות או המלצה לפעולה, ואינם מהווים תחליף לייעוץ אישי בידי בעל רישיון המתחשב בצרכיך ובנתוניך. איננו יועצי השקעות. המסחר בניירות ערך כרוך בסיכון מהותי, עד כדי אובדן מלוא ההשקעה; כל החלטה ופעולה הן באחריותך הבלעדית. i-trade ומפעיליה אינם נושאים באחריות לכל נזק, ישיר או עקיף, הנובע מהסתמכות על המידע.
Technical balance: Strong Sell (score -73.1)
✅ Analysts: avg target $4 (+1446%), strong buy
✅ Market: Market leaning positive
✅ News: Mixed sentiment
⚠️ Technical signal: Strong Sell (1↑/9↓)
⚠️ Institutional backing: 23% institutional
Below SMA 20
Price vs SMA50
-8.98%
🔴 SellBelow SMA 50
Price vs SMA100
-4.13%
🔴 SellBelow SMA 100
Price vs SMA150
-6.73%
🔴 SellBelow SMA 150
Price vs SMA200
-14.78%
🔴 SellBelow SMA 200
50/200 Cross
Death
🔴 SellLong-term downtrend
Bollinger %B
9
⚪ NeutralInside the bands
Stochastic %K
4.6
🟢 BuyOversold
RVOL
0.80
⚪ NeutralNormal volume
52-week position
12.83%
🔴 SellNear the low — relative weakness
ATR %
5.49%
⚪ NeutralHigh volatility
Recent rating changes
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Jun 8, 2026 | Ascendiant Capital | main | Buy ← Buy | $5.50 |
| Apr 8, 2026 | Ascendiant Capital | main | Buy ← Buy | $5.25 |
| Feb 23, 2026 | Ascendiant Capital | main | Buy ← Buy | $5.00 |
| Dec 9, 2025 | Ascendiant Capital | main | Buy ← Buy | $4.75 |
| Aug 26, 2025 | Ascendiant Capital | main | Buy ← Buy | $4.50 |
| Mar 6, 2025 | Alliance Global Partners | reit | Buy ← Buy | $3.50 |
| Feb 24, 2025 | Ascendiant Capital | main | Buy ← Buy | $4.25 |
| Dec 5, 2024 | Ascendiant Capital | main | Buy ← Buy | $4.00 |
Source: Yahoo Finance · consensus and targets update continuously. For thinly-covered stocks the latest rating change may be from a while ago — it's the most recent reported event, not stale data.
Next earnings
Est. EPS
-0.02
Est. revenue
$164.00K
Dividend
—
Management & founders
👤 Founders: Mr. Ram Mukunda